Axon Enterprise is trading lower today as the market digests a new round of analyst price-target reductions that emphasize margin and demand uncertainty under broader, recently announced U.S. tariff actions. In the latest notes, Morgan Stanley reiterated an Overweight rating but lowered its price target, explicitly highlighting the breadth of the April 2 tariff announcement as a risk to margins and/or demand across equipment categories; TD Cowen also lowered its price target while keeping a constructive stance on the stock.

Adding to the pressure is an approaching legal catalyst in Arizona: a Maricopa County Superior Court judge is scheduled to hear lawsuits on Friday, April 11, 2026, that could affect Axon’s proposed $1.3 billion Scottsdale headquarters development. While the outcome is not known, the hearing timing creates near-term headline risk that can weigh on sentiment for a stock already undergoing a valuation reset.

The decline comes even as Axon recently used its Axon Week 2026 event to announce new AI tools aimed at real-time intelligence and operational workflows, reinforcing the company’s push to broaden its platform beyond devices. Still, with investors focusing on profitability durability, any perceived squeeze on costs—whether from tariffs, mix, or ramp-related spending—can overwhelm product-news positives in the short run.